Companies › BeOne Medicines
21 active drug programs in 340 registered trials: 229 Phase 2, 68 Phase 1, 40 Phase 3, 3 Phase 4; Oncology, Other, Genitourinary, Immunology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sonrotoclax Tablet for Oral Suspension (BGB-11417) Bcl-2 inhibitor | BCL2 | Phase 3 | Mantle Cell Lymphoma; Chronic Lymphocytic Leukemia; CLL; Waldenstrom Macroglobulinemia … | Nov 2026 |
| Zanubrutinib Tyrosine-protein kinase BTK inhibitor | BTK | Phase 3 | B-cell Malignancies; Relapsed/Refractory Follicular Lymphoma; Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Non-Hodgkin Lymphoma … | Nov 2026 |
| BGB-43395 Cyclin-dependent kinase 4 inhibitor | CDK4 | Phase 3 | HR+/HER2- Breast Cancer; Healthy Adult Participants; Hormone-receptor-positive Breast Cancer; Advanced Solid Tumor | Nov 2026 |
| Tacabrutideg (BGB-16673) BTK inhibitor | BTK | Phase 3 | Chronic Lymphocytic Leukemia; CLL; Chronic Spontaneous Urticaria; B-cell Malignancy | Nov 2026 |
| Tislelizumab (A317) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | B-cell Malignancies; Metastatic Gastric Adenocarcinoma; Advanced Esophageal Squamous Cell Carcinoma; Advanced Unresectable Gastric Adenocarcinoma … | Dec 2026 |
| BG-C137 anti-FGFR2b antibody-drug conjugate | FGFR2 | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| BGB-B2033 Anti-glypican-3 (GPC3) antibody | GPC3 | Phase 1 | Metastatic Hepatocellular Carcinoma | Mar 2027 |
| BGB-58067 MTAP inhibitor | MTAP | Phase 1 | Healthy Volunteers; Advanced Solid Tumor | Jul 2027 |
| BGB-21447 Bcl-2 inhibitor | BCL2 | Phase 1 | Hormone-receptor-positive Breast Cancer | Jul 2027 |
| BG-C9074 | – | Phase 1 | Advanced Solid Tumor | Sep 2027 |
| BG-C0902 Bispecific anti-EGFR and anti-MET antibody-drug conjugate with topoisomerase 1 inhibitor p | EGFR, MET | Phase 1 | Solid Tumors | Nov 2027 |
| BGB-B455 anti-CLDN6 antibody-drug conjugate | CLDN6 | Phase 1 | Advanced Solid Tumor | Apr 2028 |
| BG-C477 | – | Phase 1 | Advanced Solid Tumors | Jul 2028 |
| BG-A3004 | – | Phase 1 | Skin Diseases | Aug 2028 |
| BG-89894 | – | Phase 1 | Advanced Solid Tumor | Aug 2028 |
| BG-75202 KAT6A/B inhibitor | KAT6A, KAT6B | Phase 1 | Myeloid Malignancy; Breast Cancer | Sep 2028 |
| BG-85738 RAS inhibitor (likely KRAS inhibitor) | – | Phase 1 | RAS Mutation | Sep 2028 |
| BG-T187 | – | Phase 1 | Advanced Solid Tumor | Sep 2028 |
| BG-75098 | – | Phase 1 | Advanced Solid Tumor | Nov 2028 |
| BGB-26808 Unclear - mechanism not specified in registry | – | Phase 1 | Advanced Solid Tumor | Feb 2029 |
| BG-C0979 | – | Phase 1 | Advanced Solid Tumor | Apr 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04460248 | Zanubrutinib | Phase 2 | Diffuse Large B Cell Lymphoma | Oncology | Feb 2022 |
| NCT05199909 | Zanubrutinib | Phase 2 | Antiphospholipid Syndrome | Hematology | Dec 2023 |
| NCT05972655 | Tislelizumab (A317) | Phase 2 | Low Rectal Cancer | Oncology | Aug 2024 |
| NCT05319639 | Tislelizumab (A317) | Phase 1 | Gastric Cancer Stage IV | Oncology | Oct 2024 |
| NCT05586061 | Tislelizumab (A317) | Phase 2 | HER2-positive Gastric Cancer | Oncology | Dec 2024 |
| NCT06239532 | Tislelizumab (A317) | Phase 2 | Intrahepatic Cholangiocarcinoma | Oncology | Dec 2024 |
| NCT05464433 | Tislelizumab (A317) | Phase 1 | Extranodal Natural Killer T Cell Lymphoma | Oncology | Apr 2025 |
| NCT04954781 | Tislelizumab (A317) | Phase 2 | Intrahepatic Cholangiocarcinoma | Oncology | Jul 2025 |
| NCT05758389 | Tislelizumab (A317) | Phase 2 | Head and Neck Tumors | Oncology | Aug 2025 |
| NCT05984602 | Tislelizumab (A317) | Phase 1 | Pancreatic Cancer | Oncology | Sep 2025 |
| NCT05520619 | Tislelizumab (A317) | Phase 2 | Esophageal Squamous Cell Carcinoma | Oncology | Nov 2025 |
| NCT05557578 | Tislelizumab (A317) | Phase 2 | Intrahepatic Cholangiocarcinoma | Oncology | Nov 2025 |
| NCT06032845 | Tislelizumab (A317) | Phase 2 | Solid Tumor, Adult | Oncology | Dec 2025 |
| NCT05920863 | Tislelizumab (A317) | Phase 2 | Hepatocellular Carcinoma | Oncology | Dec 2025 |
| NCT05214391 | Zanubrutinib | Phase 2 | Immune Thrombocytopenia | Hematology | Dec 2025 |
| NCT06916494 | Tislelizumab (A317) | Phase 1 | Muscle Invasive Bladder Cancer | Oncology | Jan 2026 |
| NCT06132698 | Tislelizumab (A317) | Phase 2 | NSCLC Associated With Leptomeningeal Metastases | Oncology | May 2026 |
| NCT06364956 | Tislelizumab (A317) | Phase 1 | Bladder Cancer | Oncology | Jun 2026 |
| NCT06157996 | Tislelizumab (A317) | Phase 2 | Gastric Cancer | Oncology | Aug 2026 |
| NCT05057845 | Tislelizumab (A317) | Phase 2 | Advanced Hepatocellular Carcinoma | Oncology | Sep 2026 |
| NCT07628881 | Sonrotoclax Tablet for Oral Suspension (BGB-11417) | Phase 1 | Healthy Volunteers | Other | Sep 2026 |
| NCT07590102 | BGB-58067 | Phase 1 | Healthy Volunteers | Other | Oct 2026 |
| NCT06637501 | Zanubrutinib | Phase 2 | Chronic Lymphocytic Leukemia | Oncology | Nov 2026 |
| NCT06637501 | Sonrotoclax Tablet for Oral Suspension (BGB-11417) | Phase 2 | Chronic Lymphocytic Leukemia | Oncology | Nov 2026 |
| NCT04973605 | Sonrotoclax Tablet for Oral Suspension (BGB-11417) | Phase 1 | Relapsed/Refractory Multiple Myeloma | Oncology | Nov 2026 |
| NCT06695013 | Tislelizumab (A317) | Phase 2 | B-NHL | Oncology | Nov 2026 |
| NCT06695013 | Zanubrutinib | Phase 2 | B-NHL | Oncology | Nov 2026 |
| NCT07820891 | BGB-43395 | Phase 1 | Healthy Adult Participants | Other | Nov 2026 |
| NCT06124378 | Tislelizumab (A317) | Phase 2 | Colonic Neoplasms | Oncology | Nov 2026 |
| NCT06749886 | Tislelizumab (A317) | Phase 2 | Lung Cancer | Oncology | Nov 2026 |
| NCT07005713 | Tacabrutideg (BGB-16673) | Phase 1 | Chronic Spontaneous Urticaria | Immunology | Nov 2026 |
| NCT04615143 | Tislelizumab (A317) | Phase 2 | Recurrent Hepatocellular Carcinoma | Oncology | Dec 2026 |
| NCT06647680 | Tislelizumab (A317) | Phase 2 | Rectal Cancer Patients | Oncology | Dec 2026 |
| NCT06312982 | Tislelizumab (A317) | Phase 2 | Locally Advanced Rectal Carcinoma | Oncology | Dec 2026 |
| NCT06561347 | Zanubrutinib | Phase 2 | Waldenstrom Macroglobulinemia | Oncology | Dec 2026 |
| NCT06547944 | Zanubrutinib | Phase 1 | Chronic Lymphocytic Leukemia | Oncology | Dec 2026 |
| NCT06177301 | Tislelizumab (A317) | Phase 3 | Nasopharyngeal Carcinoma | Oncology | Dec 2026 |
| NCT06838910 | Tislelizumab (A317) | Phase 2 | Thymic Carcinoma | Oncology | Dec 2026 |
| NCT07000617 | Tislelizumab (A317) | Phase 2 | NK/T Cell Lymphoma | Oncology | Dec 2026 |
| NCT07512674 | Tislelizumab (A317) | Phase 2 | Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis | Oncology | Dec 2026 |
| NCT05531123 | Tislelizumab (A317) | Phase 2 | Bladder Cancer | Oncology | Dec 2026 |
| NCT06538896 | Tislelizumab (A317) | Phase 2 | Triple-negative Breast Cancer | Oncology | Dec 2026 |
| NCT05659628 | Tislelizumab (A317) | Phase 1 | Diffuse Large B-cell Lymphoma | Oncology | Dec 2026 |
| NCT06005870 | Zanubrutinib | Phase 2 | Diffuse Large B Cell Lymphoma | Oncology | Dec 2026 |
| NCT04624958 | Zanubrutinib | Phase 2 | Mantle Cell Lymphoma | Oncology | Dec 2026 |
| NCT04850495 | Zanubrutinib | Phase 1 | Diffuse Large B-Cell Lymphoma | Oncology | Dec 2026 |
| NCT05253118 | Tislelizumab (A317) | Phase 2 | DLBCL | Oncology | Dec 2026 |
| NCT05917431 | Tislelizumab (A317) | Phase 2 | Unresectable Hepatocellular Carcinoma | Oncology | Dec 2026 |
| NCT06446726 | Tislelizumab (A317) | Phase 2 | Esophageal Squamous Cell Carcinoma | Oncology | Dec 2026 |
| NCT06211790 | Tislelizumab (A317) | Phase 2 | Kidney Cancer | Oncology | Dec 2026 |
| NCT05912816 | Tislelizumab (A317) | Phase 2 | Upper Urinary Tract Urothelial Carcinoma | Oncology | Dec 2026 |
| NCT06664021 | Tislelizumab (A317) | Phase 2 | Intrahepatic Cholangiocarcinoma | Oncology | Dec 2026 |
| NCT06356597 | Tislelizumab (A317) | Phase 2 | Colorectal Cancer | Oncology | Dec 2026 |
| NCT07126119 | Tislelizumab (A317) | Phase 2 | Upper Tract Urothelial Carcinoma | Oncology | Dec 2026 |
| NCT07125547 | Tislelizumab (A317) | Phase 2 | Ureteral Cancer | Oncology | Dec 2026 |
| NCT05837806 | Tislelizumab (A317) | Phase 2 | Neoadjuvant Immunotherapy | Other | Dec 2026 |
| NCT07233252 | Tislelizumab (A317) | Phase 2 | Renal Pelvic Carcinoma | Genitourinary | Dec 2026 |
| NCT06471738 | Zanubrutinib | Phase 2 | Ann Arbor Stage II Follicular Lymphoma | Oncology | Dec 2026 |
| NCT06625593 | BG-C137 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT04170283 | Tislelizumab (A317) | Phase 3 | B-cell Malignancies | Oncology | Dec 2026 |
The 60 nearest readouts of 340 trials; the rest in the app.
Cash of $5.8bn on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
BTK (2) BCL2 (2) CDK4 (1) MTAP (1) FGFR2 (1) PDCD1 (1) CLDN6 (1) KAT6A (1) KAT6B (1) GPC3 (1) EGFR (1) MET (1)
AstraZeneca Akeso Johnson & Johnson (Janssen) Pfizer Ono Pharmaceutical Eli Lilly Novartis AbbVie Ascentage Pharma Group Bristol-Myers Squibb
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.